You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
德琪醫藥:首款產品塞利尼索(商品名:希維奧®)獲批上市,為全球首款且唯一一款口服型XPO1抑制劑
格隆匯 12-20 16:30

格隆匯12月20日|德琪醫藥-B(6996.HK)創始人、董事長、首席執行官梅建明博士在產品獲批投資人電話會議中表示,公司首款商業化創新藥產品希維奧®於12月14日獲批上市。作為全球首款且唯一一款口服型XPO1抑制劑,希維奧®也是德琪醫藥在中國大陸獲批的第一款創新藥。

希維奧®主要針對治療復發難治性多發性骨髓瘤(rrMM)和復發難治性瀰漫性大B細胞淋巴瘤(rrDLBCL),可進行單藥及聯合用藥治療,公司預計其將於2022年第二季度正式進入商業化。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account